Carvedilol

SKU: orb2893745

Description

Carvedilol (SKF 105517) Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity. The S enantiomer of carvedilol nonselectively binds to and blocks beta-adrenergic receptors, thereby exerting negative inotropic and chronotropic effects, and leading to a reduction in cardiac output. In addition, both enantiomers of carvedilol bind to and block alpha 1-adrenergic receptors, thereby causing vasodilation and reducing peripheral vascular resistance.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 72956-09-3
• MW: 406.47
• Purity: 99.97% (May vary between batches)
• Formula: C₂₄H₂₆N₂O₄
• SMILES: COC1=CC=CC=C1OCCNCC(O)COC1=C2C(NC3=C2C=CC=C3)=CC=C1
• Target: Antibacterial,Autophagy,Adrenergic Receptor,VEGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.92 mM);Ethanol:20.3 mg/mL (49.94 mM);DMSO:40.6 mg/mL (99.88 mM)

Bioactivity

• Target IC50:
  LDL oxidation:3.8 μM|β/α1-adrenoceptor:3.8 μM
• In Vitro:
  Carvedilol rapidly inhibits Fe(++)-initiated lipid peroxidation, measured as thiobarbituric acid reactive substance (TBARS), in rat brain homogenate with an IC50 of 8.1 mM. Carvedilol protects against Fe(++)-induced alpha-tocopherol depletion in rat brain homogenate with an IC50 of 17.6 mM. Carvedilol dose-dependently decreases the intensity of the DMPO-OH signal with an IC50 of 25 mM. Carvedilol has inverse efficacy for stimulating G(s)-dependent adenylyl cyclase but stimulates phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites in beta2 adrenergic receptor (beta2AR)-expressing HEK-293 cells. Carvedilol (0.1-10 mM) produces a concentration-dependent inhibition of the mitogenesis stimulated by platelet-derived growth factor, epidermal growth factor, thrombin, and serum in human cultured pulmonary artery vascular smooth muscle cells, with IC50 values ranging from 0.3 mM to 2.0 mM. Carvedilol also produces a concentration-dependent inhibition of vascular smooth muscle cell migration induced by platelet-derived growth factor, with an IC50 value of 3 mM. Carvedilol decreases the extent of cellular vacuolization in cardiac myocytes and prevents the inhibitory effect of doxorubicin on mitochondrial respiration in both heart and liver. Carvedilol also prevents the decrease in mitochondrial Ca(2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Potassium Channel, peroxidation, SKF 105517, Vcam, VEGFR, β/α-1, inhibit, Inhibitor, lipid, inflammasome, NADPH, NLRP3, heart, LDL, HIF, failure, E-selectin, Adrenergic Receptor, blocker, BM 14190, BM14190, BM-14190, Autophagy, antihypertensive, angina, Carvedilol, Beta Receptor, congestive

Compound Identifiers

PubChem CID

2585